Theracryf (TCF)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.80p
   
  • Change Today:
      0.000p
  • 52 Week High: 4.05
  • 52 Week Low: 0.75
  • Currency: UK Pounds
  • Shares Issued: 427.35m
  • Volume: 0
  • Market Cap: £3.42m

Theracryf Overview

Evgen is a clinical stage drug development company focused on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation.

1 Day Chart (25-04-2024)

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book n/a  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Theracryf Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Mar-19 n/a (3.12) (2.70)p n/a n/a n/a n/a 0.0%
31-Mar-20 n/a (3.17) (2.07)p n/a n/a n/a n/a 0.0%
31-Mar-21 0.19 (3.21) (1.82)p n/a n/a n/a n/a 0.0%
31-Mar-22 n/a (3.17) (0.99)p n/a n/a n/a n/a 0.0%
31-Mar-23 0.44 (5.01) (1.47)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Theracryf Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Mar-25 n/a (1.40) (0.20)p n/a n/a n/a n/a 0.0%
31-Mar-26 n/a (2.20) (0.40)p n/a n/a n/a n/a 0.0%

Copyright © 2024 FactSet Research Systems Inc. All rights reserved.

Theracryf Company Announcements

Change of Name 25-Apr-2024 15:46 RNS
Holding(s) in Company 22-Apr-2024 10:11 RNS
Holding(s) in Company 11-Apr-2024 15:04 RNS

Theracryf ShareCast News

Evgen upbeat on start of glioblastoma research p... 26-Oct-2023 ShareCast
Evgen Pharma doses first volunteers in SFX-01 tr... 16-Nov-2022 ShareCast
Evgen starts recruiting volunteers for trial of ... 12-Oct-2022 ShareCast

Latest Theracryf Director Deals

Traded Action Notifier PriceAmountValue
05-Apr-24 Buy Susan (Sue) Foden 1.00p 600,000 £6,000.00
05-Apr-24 Buy Toni Hänninen 1.00p 1,000,000 £10,000.00
05-Apr-24 Placing Huw Jones 1.00p 3,000,000 £30,000.00

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

Theracryf Market Data

Currency UK Pounds
Share Price 0.80p
Change Today 0.000p
% Change 0.00 %
52 Week High 4.05
52 Week Low 0.75
Volume 0
Shares Issued 427.35m
Market Cap £3.42m

Theracryf Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
19.18% above the market average19.18% above the market average19.18% above the market average19.18% above the market average19.18% above the market average
84.91% above the sector average84.91% above the sector average84.91% above the sector average84.91% above the sector average84.91% above the sector average
Price Trend
93.46% below the market average93.46% below the market average93.46% below the market average93.46% below the market average93.46% below the market average
75.44% below the sector average75.44% below the sector average75.44% below the sector average75.44% below the sector average75.44% below the sector average
Income Not Available
Growth Not Available

Theracryf Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

Theracryf Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page